

Maintenance treatment for metastatic adenocarcinoma

A 60-year-old patient with asymptomatic, low tumor burden, pan-wild-type metastatic NSCLC

Most Common Maintenance Therapy Choices Based on Induction Regimen

Induction regimen	Most common maintenance therapy
Carboplatin/pemetrexed/bevacizumab	Pemetrexed/bevacizumab (69%)
Carboplatin/paclitaxel/bevacizumab	Bevacizumab (65%)
Carboplatin/pemetrexed	Pemetrexed (86%)

EDITOR'S COMMENTS

Maintenance treatment is entrenched in the management of metastatic adenocarcinoma, but the choice of regimen varies. GOs who use carboplatin/pemetrexed/bevacizumab are most likely to employ pemetrexed/bevacizumab as maintenance, as does Dr Wakelee. For those choosing the ECOG-E4599 regimen up front, including Dr Ramalingam, bevacizumab maintenance is the usual choice. Until the ongoing ECOG-E5508 trial confirms or refutes the suggestion from PointBreak of a benefit with combined maintenance with pemetrexed/bevacizumab, clinicians must rely on clinical judgment to make this complex decision.

SELECT REFERENCES WITH LINKS

Ciuleanu T et al. **Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study.** *Lancet* 2009;374(9699):1432-40. [Abstract](#)

Patel JD et al. **PointBreak: A randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.** *J Clin Oncol* 2013;31(34):4349-57. [Abstract](#)

Sandler A et al. **Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.** *N Engl J Med* 2006;355(24):2542-50. [Abstract](#)